Hannah Clarke

The median duration of response was 47.8 months among patients who achieved an initial complete response.

Illuccix has been previously approved in the US, Australia, Canada, and Europe.

Overall, 85% of respondents indicated they experienced frequent bladder leaks.

The software generates heatmaps to help identify prostatic tumors that may have been missed on initial reads.

At 24 months, 79% of patients experienced a response to therapy, and 56% achieved at least a 75% reduction in UUI episodes.

At a median follow-up of 40.2 months post-surgery, no patients had experienced a disease recurrence.

A phase 1/2 trial of ABO-101 is expected to launch in the first half of 2025.

In total, 28% of patients with luminal tumors and 41% of patients with nonluminal tumors experienced upstaging to nonorgan confined disease.

The primary end point is 12-month radiographic progression-free survival.

The data also showed that mortality plateaued in recent years despite declining in years prior.

Overall, 403 medical students and other applicants were matched across 148 urology residency programs nationwide.

The incidence of late grade 2 or greater GU toxicity at 5 years was 12.5% among those who did experience acute toxicity vs 7.5% among those who did not.

"What we show in our research is that cancers develop in different ways, depending on what the underlying genetic change is," says Taryn Treger.

“MPS2 could potentially improve the health of our patients by avoiding overdiagnosis and overtreatment and allowing us to focus on those who are most likely to have aggressive cancers," says Ganesh S. Palapattu, MD, FACS.

WNT9B E152K was associated with a 2.5-fold increase in the risk of prostate cancer and reached genome-wide significance.

Overall, the open-label phase 1/2 study is assessing the safety and anti-tumor activity with INKmune across 3 dose levels.

Check out the key regulatory decisions set to happen early this year.

According to the authors, these findings highlight the need to more effectively include Black men in prostate cancer research.

If approved, the marketing authorization application would be valid in all 27 European Union member states as well as in Iceland, Liechtenstein, and Norway.

64Cu-SAR-bisPSMA was previously granted a fast track designation in August 2024 for PET imaging of PSMA-positive prostate cancer lesions in patients with suspected metastasis who are candidates for initial definitive therapy.

Overall, 39% of those who received a university-formatted report and 56% of those who received a VA-formatted report were able to identify that they had prostate cancer.

At 25 weeks, FACT-P total score remained comparable between the arms.

"[The] full integration [of genomic classifier tests] into clinical practice requires additional research to better understand their cost-effectiveness, clinical utility, and impact on diverse populations," says Amir Alishahi Tabriz, MD, PhD, MPH.

"The three-year durability data from this study further validate the potential of JELMYTO in providing long-term disease control for patients with low-grade upper tract urothelial cancer,” says Solomon L. Woldu, MD.

The accuracy of PLND was 93.41% in the ICG injection arm compared with 75.91% in the control arm.

The median time to correct treatment was 98 days with initial TURBT compared with 53 days with initial mpMRI.

Functional success was achieved in 58% of patients at 5-year follow-up.

At a median follow-up of 24.3 months, the confirmed objective response rate was 70%.

The 15 drugs identified in this round of negotiations add to the 10 selected in the first round of negotiations that took place in 2023 and 2024.

The European approval of Illuccix adds on to prior approvals in the US, Australia, and Canada.